EFO
Get informed when a big investor buys or sells
+ Follow| Market cap | $25.80 Billion |
|---|---|
| Enterprise Value | $25.62 Billion |
| Dividend Yield | $1.18 (1.65%) |
| Earnings per Share | $- |
| Beta | 1.28 |
| Outstanding Shares | - |
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1962.05 |
| Enterprise Value to EBIT | -340.86 |
| Enterprise Value to Net Income | -364 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 32.11%▼ 0.94% |
|---|---|
| Total Invested | $8.43M▲ 17.98% |
| Investors Holding | 12▲ 5.00% |
No data
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...